SCHEMBL3787950

SCHEMBL3787950

CCCOc1ccc(OCCC)c(Cl)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 2/20 0.62
GLA P06280 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
L3MBTL1 Q9Y468 4/20 0.48
TDP1 Q9NUW8 2/20 0.48
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 2/20 0.47
BACE1 P56817 1/20 0.46
MAPT P10636 3/20 0.45
ATM Q13315 3/20 0.45
RAB9A P51151 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
USP2 O75604 1/20 0.44
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44
CASP1 P29466 1/20 0.44
HTT P42858 1/20 0.44
CASP7 P55210 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3785500 0.92 SMN1; SMN2 (0.59) CSNK2A1GLASMN1; SMN2L3MBTL1TDP1
SCHEMBL19612183 0.87 SMN1; SMN2 (0.55) CSNK2A1GLASMN1; SMN2L3MBTL1TDP1
SCHEMBL17433277 0.87 CSNK2A1 (0.49) CSNK2A1GLASMN1; SMN2L3MBTL1TDP1
SCHEMBL3783768 0.85 CSNK2A1 (0.49) CSNK2A1GLASMN1; SMN2L3MBTL1TDP1
SCHEMBL27569179 0.84 MRGPRX4 (0.51) CSNK2A1SMN1; SMN2ALDH1A1KDM4ERAB9A
SCHEMBL13261015 0.84 KDM4E (0.64) SMN1; SMN2L3MBTL1ALDH1A1KDM4EATM
SCHEMBL11094999 0.82 CSNK2A1 (0.42) CSNK2A1GLASMN1; SMN2L3MBTL1TDP1
SCHEMBL257320 0.82 CSNK2A1 (0.64) CSNK2A1SMN1; SMN2L3MBTL1TDP1ALDH1A1
SCHEMBL11097969 0.82 MAPT (0.46) CSNK2A1GLASMN1; SMN2L3MBTL1TDP1
SCHEMBL8560597 0.82 MAPT (0.49) CSNK2A1L3MBTL1TDP1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-04-08 US disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND NISCH, BLVRB, BBOX1 CSNK2A1 4767/4885GLA 2514/4885SMN1; SMN2 4524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.